KwdFr.i
Exploration
Accueil
Racine
Exploration
Accueil
Racine

Serveur d'exploration Tocilizumab - Exploration (Accueil)

Index « KwdFr.i » - entrée « Sclérodermie systémique (traitement médicamenteux) »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Sclérodermie systémique (sang) < Sclérodermie systémique (traitement médicamenteux) < Sclérose en plaques  Facettes :

List of bibliographic references indexed by Sclérodermie systémique (traitement médicamenteux)

Number of relevant bibliographic references: 22.
[0-20] [0 - 20][0 - 22][20-21][20-40]
Ident.Authors (with country if any)Title
000544 (2020) Carina Mihai [Suisse] ; Rucsandra Dobrota [Suisse] ; Maria Schröder [Suisse] ; Alexandru Garaiman [Suisse] ; Suzana Jordan [Suisse] ; Mike Oliver Becker [Suisse] ; Britta Maurer [Suisse] ; Oliver Distler [Suisse]COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD.
000F93 (2019) Yoshihito Shima [Japon] ; Yasushi Kawaguchi [Japon] ; Masataka Kuwana [Japon]Add-on tocilizumab versus conventional treatment for systemic sclerosis, and cytokine analysis to identify an endotype to tocilizumab therapy.
001113 (2018) Andreu Fernández-Codina [Espagne] ; Kyle M. Walker [Canada] ; Janet E. Pope [Canada]Treatment Algorithms for Systemic Sclerosis According to Experts.
001122 (2018) M. Kono [Japon] ; S. Yasuda [Japon] ; M. Kono [Japon] ; T. Atsumi [Japon]Tocilizumab reduced production of systemic sclerosis-related autoantibodies and anti-cyclic citrullinated protein antibodies in two patients with overlapping systemic sclerosis and rheumatoid arthritis.
001149 (2018) Christopher P. Denton [Royaume-Uni] ; Voon H. Ong [Royaume-Uni] ; Shiwen Xu [Royaume-Uni] ; Haiyin Chen-Harris [États-Unis] ; Zora Modrusan [États-Unis] ; Robert Lafyatis [États-Unis] ; Dinesh Khanna [États-Unis] ; Angelika Jahreis [États-Unis] ; Jeffrey Siegel [États-Unis] ; Thierry Sornasse [États-Unis]Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.
001268 (2018) Galia Zacay [Israël] ; Yair Levy [Israël]Outcomes of patients with systemic sclerosis treated with tocilizumab: Case series and review of the literature.
001560 (2017) Cosimo Bruni [Italie] ; Emanuela Praino [Italie] ; Yannick Allanore [France] ; Oliver Distler [Suisse] ; Armando Gabrielli [Italie] ; Florenzo Iannone [Italie] ; Marco Matucci-Cerinic [Italie]Use of biologics and other novel therapies for the treatment of systemic sclerosis.
001682 (2017) Dinesh Khanna [États-Unis] ; Christopher P. Denton [Royaume-Uni] ; Celia J F. Lin [États-Unis] ; Jacob M. Van Laar [Pays-Bas] ; Tracy M. Frech [États-Unis] ; Marina E. Anderson [Royaume-Uni] ; Murray Baron [Canada] ; Lorinda Chung [États-Unis] ; Gerhard Fierlbeck [Allemagne] ; Santhanam Lakshminarayanan [États-Unis] ; Yannick Allanore [France] ; Janet E. Pope [Canada] ; Gabriela Riemekasten [Allemagne] ; Virginia Steen [États-Unis] ; Ulf Müller-Ladner [Allemagne] ; Helen Spotswood [Royaume-Uni] ; Laura Burke [Royaume-Uni] ; Jeffrey Siegel [États-Unis] ; Angelika Jahreis [États-Unis] ; Daniel E. Furst [États-Unis]Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)
001856 (2017) Takashi Taniguchi [Japon] ; Yoshihide Asano [Japon] ; Takemichi Fukasawa [Japon] ; Ayumi Yoshizaki [Japon] ; Shinichi Sato [Japon]Critical contribution of the interleukin-6/signal transducer and activator of transcription 3 axis to vasculopathy associated with systemic sclerosis.
001995 (2016) Oliver Distler [Suisse] ; Jörg H W. Distler [Allemagne]Tocilizumab for systemic sclerosis: implications for future trials.
001A41 (2016) Lazaros I. Sakkas [Grèce]Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis.
001A51 (2016) Dinesh Khanna [États-Unis] ; Christopher P. Denton [Royaume-Uni] ; Angelika Jahreis [États-Unis] ; Jacob M. Van Laar [Pays-Bas] ; Tracy M. Frech [États-Unis] ; Marina E. Anderson [Royaume-Uni] ; Murray Baron [Canada] ; Lorinda Chung [États-Unis] ; Gerhard Fierlbeck [Allemagne] ; Santhanam Lakshminarayanan [États-Unis] ; Yannick Allanore [France] ; Janet E. Pope [Canada] ; Gabriela Riemekasten [Allemagne] ; Virginia Steen [États-Unis] ; Ulf Müller-Ladner [Allemagne] ; Robert Lafyatis [États-Unis] ; Giuseppina Stifano [États-Unis] ; Helen Spotswood [Royaume-Uni] ; Haiyin Chen-Harris [États-Unis] ; Sebastian Dziadek [Suisse] ; Alyssa Morimoto [États-Unis] ; Thierry Sornasse [États-Unis] ; Jeffrey Siegel [États-Unis] ; Daniel E. Furst [États-Unis]Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.
001C86 (2016) Özgül Mu Tu Koryürek ; Göknur Kalkan [Turquie]A new alternative therapy in dermatology: tocilizumab.
001E45 (2015) Marisa Fernandes Das Neves [Portugal] ; Susana Oliveira [Portugal] ; Marta C. Amaral [Portugal] ; José Delgado Alves [Portugal]Treatment of systemic sclerosis with tocilizumab.
001E85 (2015) M. Ollé [Espagne]The European League Against Rheumatism (EULAR) - 16th Annual European Congress (June 10-13, 2015 - Rome, Italy).
002026 (2015) Yoshihito Shima [Japon] ; Naoki Hosen ; Toru Hirano ; Junsuke Arimitsu ; Sumiyuki Nishida ; Keisuke Hagihara ; Masashi Narazaki ; Atsushi Ogata ; Toshio Tanaka ; Tadamitsu Kishimoto ; Atsushi KumanogohExpansion of range of joint motion following treatment of systemic sclerosis with tocilizumab.
002385 (2014) Zsuzsanna Hortobagyi Mcmahan [États-Unis] ; Fredrick M. WigleyNovel investigational agents for the treatment of scleroderma.
002526 (2014) Masahiro Kondo [Japon] ; Yohko Murakawa [Japon] ; Takeshi Matsumura [Japon] ; Osamu Matsumoto [Japon] ; Mariko Taira [Japon] ; Mayuko Moriyama [Japon] ; Yoshiko Sumita [Japon] ; Shuhei Yamaguchi [Japon]A case of overlap syndrome successfully treated with tocilizumab: a hopeful treatment strategy for refractory dermatomyositis?
002664 (2013) Rieke Alten [Allemagne] ; Tazio MaleitzkeTocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases.
002739 (2013) Ivan Foeldvari [Allemagne]New developments in juvenile systemic and localized scleroderma.
003C90 (2010) Yoshihito Shima [Japon] ; Yusuke Kuwahara [Japon] ; Hiroyuki Murota [Japon] ; Shun Kitaba [Japon] ; Mari Kawai [Japon] ; Toru Hirano [Japon] ; Junsuke Arimitsu [Japon] ; Masashi Narazaki [Japon] ; Keisuke Hagihara [Japon] ; Atsushi Ogata [Japon] ; Ichiro Katayama [Japon] ; Ichiro Kawase [Japon] ; Tadamitsu Kishimoto [Japon] ; Toshio Tanaka [Japon]The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdFr.i -k "Sclérodermie systémique (traitement médicamenteux)" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdFr.i  \
                -Sk "Sclérodermie systémique (traitement médicamenteux)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    KwdFr.i
   |clé=    Sclérodermie systémique (traitement médicamenteux)
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021